Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | DRD1 | P21728 | 3/20 | 0.39 |
| ▸ | DRD5 | P21918 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutamic Acid SCHEMBL161108 | 0.88 | MCHR1 (0.46) | SLC1A3SLC1A2SLC1A1HTR2AHTR2C | |
| SCHEMBL160943 | 0.77 | HTR2A (0.55) | HTR2AHTR2CHTR2BNOTUMDRD2 | |
| SCHEMBL6883015 | 0.72 | MAOA (0.59) | HTR2AHTR2CHTR2BDRD2DRD3 | |
| Aspartic Acid SCHEMBL162171 | 0.72 | DPP8 (0.45) | HTR2AHTR2BHDAC8GRIK1DRD2 | |
| Nitric Acid SCHEMBL165780 | 0.72 | HTR2A (0.50) | HTR2AHTR2CHTR2BMCHR1NOTUM | |
| Lorcaserin SCHEMBL15389882 | 0.72 | HTR2A (0.64) | SLC1A3SLC1A2SLC1A1HTR2AHTR2C | |
| Lorcaserin SCHEMBL175421 | 0.72 | HTR2A (0.64) | SLC1A3SLC1A2SLC1A1HTR2AHTR2C | |
| Lorcaserin SCHEMBL174127 | 0.72 | HTR2A (0.64) | SLC1A3SLC1A2SLC1A1HTR2AHTR2C | |
| SCHEMBL29991420 | 0.70 | MAOA (0.55) | HTR2AHTR2CHTR2BNOTUMDRD2 | |
| SCHEMBL2625798 | 0.70 | MAOA (0.55) | HTR2AHTR2CHTR2BNOTUMDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611449-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | Arena Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030939-A1 | ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |